Sutimlimab-jome (Enjaymo®)

Covered only when all criteria are met; excluded are patients <18 years or <39 kg, asymptomatic patients, those without chronic hemolysis, or with secondary causes not excluded. Key requirements: age ≥18 and weight ≥39 kg, symptomatic CAD with evidence of chronic hemolysis, DAT strongly positive for C3d with IgG negative/weak, cold agglutinin titer ≥64 at 4°C, baseline hemoglobin ~6–10 g/dL and elevated total bilirubin, hematology prescriber/consultation, adherence to specified weight‑based IV dosing, and approval limited to 1 year.

"Enjaymo is indicated for the treatment of individuals with cold agglutinin disease."

Sign up to see full coverage criteria, indications, and limitations.